MORC3 and dermatomyositis: NXP-2 antibody positivity has been associated with more refractory DM requiring treatments such as IVIG and rituximab beyond first-line therapies, such as prednisone and disease-modifying drugs (i.e., methotrexate and azathioprine) [11].